Cheap gout drug tested as COVID-19 treatment
NCT ID NCT06847204
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed trial tested whether colchicine, a cheap anti-inflammatory drug used for gout, can help patients with mild to moderate COVID-19 pneumonia. Sixty-six patients in Lahore were given the drug to see if it shortens hospital stays and reduces oxygen needs. The goal is to find an affordable treatment option for developing countries.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Colchicine (an anti-inflammatory drug, commonly used for gout)
- What this could lead to
- If it works, this could point toward an affordable treatment option for COVID-19 pneumonia in developing countries.
- What could go wrong
- This is a small, early-phase trial (Phase 1/2) with only 66 participants, so results may not be conclusive or apply to all patients. Colchicine also has known side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
General hospital
Lahore, Punjab Province, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?